ライフサイエンスコーパス: mucus hypersecretion

1 hat involves airway hyper-responsiveness and mucus hypersecretion.

2 with the severity of airway inflammation and mucus hypersecretion.

3 esulting in increased airway eosinophils and mucus hypersecretion.

4 ion, goblet cell hyperplasia/metaplasia, and mucus hypersecretion.

5 hyperresponsiveness (AHR), inflammation, and mucus hypersecretion.

6 e associated with goblet cell metaplasia and mucus hypersecretion.

7 choconstriction, parenchymal destruction and mucus hypersecretion.

8 al implications for the management of airway mucus hypersecretion.

9 inflammatory airway diseases associated with mucus hypersecretion.

10 erbations, which are associated with further mucus hypersecretion.

11 ts for pharmacological intervention to treat mucus hypersecretion.

12 age fluid and airway tissue eosinophilia and mucus hypersecretion.

13 inophil infiltration, VCAM-1 expression, and mucus hypersecretion.

14 onses and increases viral titres, leading to mucus hypersecretion.

15 nhibitor NU7441 reduced airway eosinophilia, mucus hypersecretion, airway hyperresponsiveness, and OV

16 re, wild-type mice had chronic inflammation, mucus hypersecretion, airway remodeling, emphysema, and

17 irway disease characterized by inflammation, mucus hypersecretion and abnormal airway smooth muscle (

18 chronic airway inflammation, which leads to mucus hypersecretion and airway hyperresponsiveness.

19 Remodeling processes, such as mucus hypersecretion and extracellular matrix protein pr

20 strate that Lyn overexpression decreased the mucus hypersecretion and levels of the muc5ac transcript

21 ponse of the airways that is associated with mucus hypersecretion and obstruction of small airways.

22 Mucus hypersecretion and persistent airway inflammation

23 pha-deficient animals specifically inhibited mucus hypersecretion and reduced IL-13.

24 l infiltration, goblet cell hyperplasia with mucus hypersecretion, and accumulation and activation of

25 eactivity, eosinophilic airway inflammation, mucus hypersecretion, and Ag-specific Ig production.

26 nophilic inflammation, Th2 cytokine release, mucus hypersecretion, and AHR.

27 reduction in airway eosinophil infiltration, mucus hypersecretion, and airway hyperreactivity in resp

28 nal features of asthma: airway eosinophilia, mucus hypersecretion, and airway hyperreactivity.

29 characterized by eosinophilic inflammation, mucus hypersecretion, and airway hyperresponsiveness (AH

30 sease that is characterized by inflammation, mucus hypersecretion, and airway hyperresponsiveness.

31 airway hyperresponsiveness, gene expression, mucus hypersecretion, and airway inflammation was assess

32 However, goblet cell metaplasia, mucus hypersecretion, and airway obstruction are integra

33 t also reduced airway hyperreactivity (AHR), mucus hypersecretion, and fibrosis.

34 reased allergen-induced airway inflammation, mucus hypersecretion, and hyperresponsiveness in the hGX

35 associated with a reduction in eosinophilia, mucus hypersecretion, and IL-5 and IL-13 production upon

36 ve as a therapeutic target for inflammation, mucus hypersecretion, and structural lung damage and ind

37 ainst ovalbumin-induced airway eosinophilia, mucus hypersecretion, and Th2 cytokine production (IL-4/

38 leading to eosinophilic airway inflammation, mucus hypersecretion, and Th2 cytokine production in res

39 the development of AHR, airway eosinophilia, mucus hypersecretion, and TH2 cytokine production withou

40 racterized by airway epithelial cell damage, mucus hypersecretion, and Th2 cytokine production.

41 Eosinophil recruitment and mucus hypersecretion are characteristic of asthmatic air

42 Goblet cell metaplasia and mucus hypersecretion are important features in the patho

43 A-induced inflammatory cell infiltration and mucus hypersecretion as observed in lung sections, and m

44 ungs were examined for cell infiltration and mucus hypersecretion, as well as the expression of antio

45 ncy also diminished goblet cell hyperplasia, mucus hypersecretion, bronchoalveolar lavage eosinophili

46 allergen-induced airway hyperreactivity and mucus hypersecretion but not for fibroblast or alternati

47 However, IL-6 is essential for mucus hypersecretion by airway epithelial cells triggere

48 ssibility that adenosine also contributes to mucus hypersecretion by airway epithelial cells.

49 d that Lyn overexpression ameliorated airway mucus hypersecretion by down-regulating STAT6 and its bi

50 monstrated that M. pneumoniae induces airway mucus hypersecretion by modulating the STAT/EGFR-FOXA2 s

51 tive Rho-A/Rho kinase inhibitor, affects the mucus hypersecretion by suppressing MUC5AC via signal tr

52 the mechanism by which M. pneumoniae induces mucus hypersecretion by using M. pneumoniae infection of

53 Chronic mucus hypersecretion (CMH) is common among smokers and i

54 ntly reduced airway eosinophil infiltration, mucus hypersecretion, edema, and IL-4 levels in a mouse

55 se, airway hyperreactivity, T(H)2 responses, mucus hypersecretion, eosinophil infiltration, and colla

56 ased bronchoalveolar lavage eosinophilia and mucus hypersecretion following the secondary challenge p

57 lar infiltration with concomitant epithelial mucus hypersecretion, goblet cell metaplasia, subepithel

58 TH2-mediated goblet cell differentiation and mucus hypersecretion in a murine model of allergic lung

59 However, its function in modulating airway mucus hypersecretion in asthma remains undefined.

60 hypersecretory drugs for treatment of airway mucus hypersecretion in asthma.

61 nd implicate NKCC1 in the pathophysiology of mucus hypersecretion in asthma.

62 airway inflammation and hyperreactivity and mucus hypersecretion in house dust mite-challenged mice.

63 ggest that propofol (Diprivan) may stimulate mucus hypersecretion in patients without pulmonary disea

64 mice, there was no goblet cell metaplasia or mucus hypersecretion in response to OVA, even in the pre

65 2 cytokine production in the peritoneum, or mucus hypersecretion in the gastrointestinal tract.

66 ant mediators of the eosinophilic influx and mucus hypersecretion in the lungs in a murine model of a

67 in diminished eosinophilic inflammation and mucus hypersecretion in the lungs of allergen-sensitized

68 Mucus hypersecretion is a common characteristic of asthm

69 Airway mucus hypersecretion is a feature of many patients with

70 Mucus hypersecretion is a hallmark of asthma that contri

71 Airway mucus hypersecretion is a key pathophysiologic feature i

72 Airway mucus hypersecretion is a key pathophysiological feature

73 Mucus hypersecretion is a prominent manifestation in pat

74 Mucus hypersecretion is a prominent manifestation in pat

75 Because mucus hypersecretion is common in purulent rhinitis, we

76 g events such as epithelial desquamation and mucus hypersecretion leading to airway obstruction, sube

77 e damage, inflammatory cell recruitment, and mucus hypersecretion may be associated with substantial

78 IL-11 did not cause a comparable decrease in mucus hypersecretion, Muc 5ac gene expression, or the le

79 Airway inflammation and mucus hypersecretion/overproduction/obstruction are path

80 , which includes recruitment of eosinophils, mucus hypersecretion, Th2 cytokine production, and airwa

81 nflammation, airway hyperresponsiveness, and mucus hypersecretion to a similar degree as detected in

82 hyperresponsiveness, lung inflammation, and mucus hypersecretion to the degree observed in wild-type

83 Mucus hypersecretion upon Pofut1 inactivation is accompa

84 acterized by airway eosinophilia, as well as mucus hypersecretion, which can lead to airflow obstruct

85 lic inflammation, Th2 cell accumulation, and mucus hypersecretion with mucus metaplasia.

86 cell hypertrophy and hyperplasia as well as mucus hypersecretion with subsequent airflow obstruction

87 rly suppressed AHR, airway eosinophilia, and mucus hypersecretion without any reduction in TH2 cytoki